Results 71 to 80 of about 98,172 (269)
Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology
Angewandte Chemie, Volume 137, Issue 28, July 7, 2025.Targeted protein degradation (TPD) has emerged as a powerful therapeutic approach, with numerous candidates molecules now advancing into clinical development. Recent innovations have incorporated nanoparticles to facilitate and enhance these degradation processes, yielding synergistic effects.
Andrew G. Baker +3 more
wiley +2 more sources
Andrology, EarlyView.Abstract Background Imatinib and dasatinib are tyrosine kinase inhibitors (TKIs) increasingly used to treat several diseases in both children and adults at fertile age. We have previously shown that imatinib has adverse effects on developing testis, and imatinib‐treated male patients have been reported to have reduced sperm counts.
Anna Eggert +10 more
wiley +1 more source
Advanced Science, 2022 The Bcr/Abl plays a central role in Philadelphia chromosome‐positive (Ph+) leukemia because of the constitutively activated Abl tyrosine kinase and its downstream pathways.
Bohan Ma +8 more
doaj +1 more source
ANZ Journal of Surgery, EarlyView.Costs of neoadjuvant therapy. ABSTRACT Purpose Total neoadjuvant therapy (TNT) has become the standard of care in locally advanced rectal cancer, but its economic impact is unclear. This study compares the cost of TNT with conventional neoadjuvant therapy (CNT), consisting of either short‐course radiotherapy or long‐course chemoradiotherapy, within a ...
Ishraq Murshed +6 more
wiley +1 more source
Hematology Reports, 2012 Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is mediated by different mechanisms that can be classified as BCR-ABL dependent or BCR-ABL independent pathways.
Marjanu Hikmah Elias +7 more
doaj +1 more source
α-bisabolol is an effective proapoptotic agent against BCR-ABL(+) cells in synergism with Imatinib and Nilotinib. [PDF]
PLoS ONE, 2012 We showed that α-bisabolol is active against primary acute leukemia cells, including BCR-ABL(+) acute lymphoblastic leukemias (ALL). Here we studied the activity of α-bisabolol against BCR-ABL(+) cells using 3 cell lines (K562, LAMA-84, CML-T1) and 10 ...
Massimiliano Bonifacio +8 more
doaj +1 more source
Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1
British Journal of Haematology, EarlyView.Summary Acute myeloid leukaemia (AML) is a severe disease occurring mainly in the elderly population. Venetoclax (VEN) combined with azacitidine has changed the paradigm of treatment of AML. Nevertheless, approximately 30% of patients are primary refractory to VEN (VEN‐R), with no current therapeutic option.
Sylvain Garciaz +12 more
wiley +1 more source
BCR-ABL rearrangement is not detectable in essential thrombocythemia [PDF]
Blood, 2001 Essential thrombocythemia (ET) is a chronic myeloproliferative disorder (MPD) characterized by an elevated thrombocytosis, an increased number of megakaryocytes with dismegakaryopoiesis in the bone marrow, and no identifiable underlying primary causes. The disease can evolve into myelofibrosis and,
EMILIA G. +12 more
openaire +5 more sources
British Journal of Haematology, EarlyView.A retrospective study from 11 institutions was performed in 139 chronic myeloid leukaemia (CML) patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13–88 years) and 53 years (range, 18–91 years). After a median follow‐up of 85 months, the median time from diagnosis of CML to secondary
Yingling Zu +17 more
wiley +1 more source
British Journal of Haematology, EarlyView.Inherited thrombocytopenia (IT) caused by germline variants in RUNX1, ETV6 or ANKRD26 carries a high risk of developing haematological malignancy. This study examined the clinical, platelet and molecular characteristics of 66 patients with these conditions, who carried 24 distinct genetic variants in the corresponding genes.
Ana Marín‐Quílez +34 more
wiley +1 more source